Clinical Trial Update: Trial of Switching Between Intravitreal Bevacizumab (Avastin®)& Intravitreal Dexamethasone (Ozurdex™) for Persistent Diabetic Macular Oedema [Phase 2]

View source ↗

Summary

Phase 2 trial comparing switching between intravitreal bevacizumab and intravitreal dexamethasone for persistent diabetic macular edema have completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes
• Diabetic Macular Edema
• Diabetic Macular Oedema
• Diabetic Retinopathy

Drugs mentioned

• Bevacizumab (bevacizumab)
• Dexamethasone intravitreal implant (Dexamethasone)

Snippet

Sponsor: University of Sydney | Conditions: Diabetes, Diabetic Macular Oedema | Phase 2 | Status: COMPLETED